Catalyst Pharmaceuticals, Inc.
CPRX
Peringkat dalam Saham
#4170
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Harga Saham
$31.49
Terakhir disinkronkan: 2026-07-21
Kapitalisasi Pasar
$3.85B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
53.24%
Negara
US
Perdagangan Catalyst Pharmaceuticals, Inc. (CPRX)
Kategori
Healthcare
EPS untuk Catalyst Pharmaceuticals, Inc. (CPRX)
EPS per March 2026 TTM: $1.80
Menurut laporan keuangan terbaru dan harga saham Catalyst Pharmaceuticals, Inc., EPS perusahaan saat ini (TTM) adalah $1.80. Pada akhir 2023, perusahaan memiliki EPS sebesar $0.67 penurunan dibandingkan dengan EPS tahun 2022 sebesar $0.80.
Riwayat EPS untuk Catalyst Pharmaceuticals, Inc. dari 2002 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| 2026 (TTM) | $1.80 | 30.43% |
| 2024 | $1.38 | 105.97% |
| 2023 | $0.67 | -16.25% |
| 2022 | $0.80 | 110.53% |
| 2021 | $0.38 | -47.22% |
| 2020 | $0.72 | 132.26% |
| 2019 | $0.31 | -193.94% |
| 2018 | $-0.33 | 57.14% |
| 2017 | $-0.21 | -4.55% |
| 2016 | $-0.22 | -12.00% |
| 2015 | $-0.25 | 4.17% |
| 2014 | $-0.24 | -11.11% |
| 2013 | $-0.27 | 92.86% |
| 2012 | $-0.14 | -51.72% |
| 2011 | $-0.29 | 31.82% |
| 2010 | $-0.22 | -54.17% |
| 2009 | $-0.48 | -40.74% |
| 2008 | $-0.81 | 145.45% |
| 2007 | $-0.33 | -8.33% |
| 2006 | $-0.36 | 24.14% |
| 2005 | $-0.29 | 61.11% |
| 2004 | $-0.18 | 20.00% |
| 2003 | $-0.15 | 36.36% |
| 2002 | $-0.11 | 0.00% |
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $17.32 | 862.22% |
US
|
|
| $-7.98 | -543.33% |
US
|
|
| $-5.29 | -393.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,441.11% |
NL
|
